May 2025
Pivotal readouts on deck as Takeda sees stagnant sales this year
Takeda, Phase 3, Pivotal, Growth, Sales – occupational activity, JPY
Blood cancer biotech Vor Bio ends clinical work, lays off 95% of staff
Hematologic Neoplasms, Leukemia, Myelocytic, Acute, Reflex, Vestibulo-Ocular, gene therapy, 95%
AI Drug Discovery Firm Insitro Lays Off 22% of Workforce Amid Ongoing Biotech Market Turmoil
Insitro, AI drug discovery, biotechnology layoffs, workforce reduction, tumultuous market, industry restructuring, biotech market trends, clinic readiness, cost-cutting, 2025 biotech layoffs
Takeda announces handful of pipeline cuts in effort to pivot resources
Takeda, pipeline, restructuring, Solid Neoplasm, pivot resources
Gilead tees up $11B in new US manufacturing, R&D investments
United States, Investments, Manufacture, R&D, Billion, U.S.
In first oncology expert meeting under Makary, FDA spotlights cancer drugs from J&J, Pfizer, Roche and UroGen
United States Food and Drug Administration, oncology expert, J&J, Pfizer, Roche (company), UroGen
Teva plots thousands of job cuts as restructuring drive enters ‘acceleration’ phase
Workforce reduction (8%), $700 million cost savings, Strategic overhaul, Generics to biopharmaceuticals pivot, Operational streamlining, R&D investment
FDA Vaccine Advisory Committee to Determine 2025-2026 COVID-19 Vaccine Formulation
COVID-19 vaccines, FDA advisory committee, strain selection, 2025-2026 formula, vaccine updates, VRBPAC meeting
Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides
MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1
Biotech stocks plunge and industry figures left to wonder after Prasad’s FDA appointment
United States Food and Drug Administration, Industry, Prasad, Appointments, stocks, Cell Therapy, Market, figures